Ideaya Biosciences

Ideaya Biosciences is one of the...

• Russell 3000.

Ideaya Biosciences is a company listed under the stock ticker IDYA (US).

View the org chart displaying its 18 main executives

Most searched biographies at Ideaya Biosciences

• Yujiro Hata, Chief Executive Officer and Director
• Susan Kelley, Director
• Garret Hampton, Director

Popular executive movements at Ideaya Biosciences

• Daniel Simon has joined the company as Chief Business Officer  (posted on May 29 2024).

Create your alert
to follow the executive moves at Ideaya Biosciences.

Ideaya Biosciences has 2,291 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Merck has announced the acquisition of EyeBio  (posted on May 31 2024).
• Actuate Therapeutics has just announced a $50 Million fundraising (posted on May 29 2024).
• Grey Wolf Therapeutics has just announced a $50 Million fundraising (posted on May 25 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio
• Kristina Burow - Director at Scholar Rock

Learn more about the Biotechnology industry >

Press releases by Ideaya Biosciences

• Investor Relations | IDEAYA Biosciences - News ReleasesBack ButtonSearch IconFilter Icon
• IDEAYA to Participate in Upcoming November 2020 Investor Relations Events - IDEAYA Biosciences
• IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform - IDEAYA Biosciences
• IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations - IDEAYA Biosciences
• IDEAYA to Participate in Upcoming September 2020 Investor Relations Events - IDEAYA Biosciences
• IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update - IDEAYA Biosciences
• IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment - IDEAYA Biosciences
• IDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ/11 Basket Trial - IDEAYA Biosciences
• IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12, 2020 - IDEAYA Biosciences
• IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor - IDEAYA Biosciences
• View more press releases Close

Social media about Ideaya Biosciences

• Ideaya Biosciences on Wikipedia, Google News & Yahoo Finance
• Ideaya Biosciences on LinkedIn, Twitter & YouTube

Contact by email its executives including Yujiro Hata

Call Ideaya Biosciences at +1 650...

View the org chart

Register to receive your alert

Report an error